Key events, in time order
Pomerantz files suit alleging securities violations from 2025-03-31 to 2026-04-17
Priced at-the-market, 8M shares plus warrants; proceeds for working capital
Revenue ~$4.0-4.1M, cash $31.4M; assessing impairments, going-concern doubt raised
Q1 revenue up 53% to $4.3M, but hardware narrative hit, guidance scrapped, cash dwindles
None yet
None yet
Nano-X Imaging (NNOX) is mentioned in upcoming earnings reports. The discussion is focused on scheduled financial events, not the company's technology or performance.
Main discussion
#earnings before the open on Friday, July 31, 2026 https://www.earningswhispers.com/calendar $XOM $ABBV $CCJ $CVX $MRNA $AN $ETN $MGA $D $ABR $CL $CHD $BTSG $BLDP $CRI $EQX $ENB $FRT $FET $IMO $LIN $LEA $NNOX $WT $VEON $TROW $TAC $SAMG $RBC $PRM $PRLB $POR $PAX $NWL $NVT $MOG.A $
Today's Key Events (All EST) — 07/31/2026 06:00: $ARES 06:00: Patria $PAX 06:00: Proto Labs $PRLB 06:00: Perimeter Solutions $PRM 06:05: AngloGold Ashanti $AU 06:10: Carter’s $CRI 06:15: Chevron $CVX 06:30: Exxon Mobil $XOM 06:30: Eaton $ETN 06:30: Lear $LEA 06:30: LyondellBasell
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Nano-X makes a cheaper, semiconductor-based digital X-ray machine (Nanox.ARC) plus cloud software for remote scan reading and AI analysis of existing CT images. Think of it as trying to be the low-cost disruptor in medical imaging hardware.
Revenue is tiny at USD 0.01B annually, and the company loses money on every sale—gross margin is deeply negative (-85.67% TTM). No recurring profit stream exists; it burns cash on hardware development and services.
No visible moat: the ARC is still a prototype, and established giants like GE HealthCare and Siemens Healthineers dominate imaging with proven products and sales networks. Nano-X has no pricing power, no installed base, and its AI/teleradiology services face e
